RxDoctor Payments Data

Katelyn Stack

Nurse Practitioner · Albany, NYNPI 1588329502

Payments from drug & device makers

$1,891in general payments, 2019–2025

Across 73 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$282
  • Sumitomo Pharma America, Inc.$265
  • Axonics, Inc.$166
  • Boston Scientific$143
  • AbbVie$141
  • Astellas Pharma US Inc$124
  • plus $770 from 12 others

What the payments were for

  • Food & beverage$1,82697%
  • Education$653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,891 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$38,759
Medicare patients
256
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron79$84,285
MyrbetriqMirabegron49$43,008
Tamsulosin Hcl480$7,617
Estradiol50$4,215
Finasteride207$3,217
Silodosin20$1,492
Methenamine Hippurate26$1,442
Potassium Citrate ErPotassium Citrate16$1,332
Dutasteride58$1,221
Alfuzosin Hcl ErAlfuzosin Hcl65$1,211
Oxybutynin Chloride ErOxybutynin Chloride38$1,000
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$645
Tadalafil15$641
Ciprofloxacin Hcl52$254
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$265$84,28579 claims
Astellas Pharma US IncMyrbetriq$124$43,00849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →